[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product].
Following application of Silentan coated tablets (a combination of acetylsalicylic acid, caffeine, diazepam and dihydroergotamine (DHE) tartrate) in six healthy male volunteers serum concentrations were determined. The estimated relative bioavailabilities of these substances in the commercially available drug were compared to the encapsulated single substances. For acetylsalicylic acid and caffeine there were nearly no differences to be observed. Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.
D000328:Adult; D001241:Aspirin / Q000378:metabolism*; D001682:Biological Availability; D002110:Caffeine / Q000378:metabolism*; D003975:Diazepam / Q000378:metabolism*; D004087:Dihydroergotamine / Q000378:metabolism*; D004338:Drug Combinations; D006801:Humans; D007700:Kinetics; D008297:Male
D004338:Drug Combinations; D002110:Caffeine; D004087:Dihydroergotamine; C019087:Silentan; D003975:Diazepam; D001241:Aspirin
Vergleichende Pharmakokinetik und relative Bioverfügbarkeit der Wirkstoffe Diazepam, Acetylsalicylsäure, Coffein und Dihydroergotamin-tartrat in einem Kombinationspräparat.